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ABSTRACT
Purpose Subcutaneously or intramuscularly administered
biodegradable microsphere formulations have been success-
fully exploited in the management of chronic conditions for
over two decades, yet mechanistic understanding of the im-
pact of formulation attributes on in vivo absorption rate from
such systems is still in its infancy.
Methods Suspension formulation physicochemical attributes
may impact particulate deposition in subcutaneous (s.c.) tissue.
Hence, the utility of synchrotron X-ray micro-computed to-
mography (μCT) for assessment of spatial distribution of sus-
pension formulation components (PLG microspheres and ve-
hicle) was evaluated in a porcine s.c. tissue model. Optical
imaging of dyed vehicle and subsequent microscopic assess-
ment of microsphere deposition was performed in parallel to
compare the two approaches.
Results Our findings demonstrate that synchrotron μCT can
be applied to the assessment of microsphere and vehicle dis-
tribution in s.c. tissue, and that microspheres can also be
visualised in the absence of contrast agent using this approach.
The technique was deemed superior to optical imaging of
macrotomy for the characterisation of microsphere deposition
owing to its non-invasive nature and relatively rapid data ac-
quisition time.
Conclusions The method outlined in this study provides a
proof of concept feasibility for μCT application to determin-
ing the vehicle and suspended PLG microspheres fate follow-
ing s.c. injection. A potential application for our findings is
understanding the impact of injection, device and formulation
variables on initial and temporal depot geometry in pre-
clinical or ex-vivo models that can inform product design.
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INTRODUCTION
Self-administration of long acting formulations via subcutane-
ous (s.c.) or intramuscular (i.m.) injection is an attractive treat-
ment paradigm in a range of chronic conditions (e.g. type 2
diabetes, schizophrenia, acromegaly), contributing to im-
proved patient adherence and tolerability through reduction
of peak-to-trough plasma concentration ratios. Encapsulation
of active pharmaceutical ingredients (APIs) within biodegrad-
able polylactide-co-glycolide (PLG) microspheres has been
exploited commercially as a drug delivery platform providing
sustained release of therapeutic agents following subcutaneous
or intramuscular injection. Examples include BYDUREON®
(AstraZeneca Pharmaceuticals) [1], RISPERDAL®
CONSTA® (Janssen Pharmaceuticals) [2], VIVITROL®
(Alkermes) [3], and Sandostatin LAR® (Novartis
Pharmaceuticals) [4], which are all based on the Medisorb®
microsphere technology (Alkermes, Inc.).
Factors governing the rate of appearance of API within the
systemic circulation following subcutaneous injection of solu-
tions have been extensively reviewed elsewhere [5–8].
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Following injection, API is transported through the intersti-
tium by diffusion and convection mechanisms before uptake
by venous and/or lymphatic capillaries. The extent of spread
and resultant interfacial surface area of the injected depot
impacts i) the diffusional path length for the API ii) the inter-
stitial pressure which influences convectional flow rate and iii)
interaction with metabolic and immune processes within the
subcutaneous tissue. Injection force, volume, viscosity, osmo-
lality and interfacial tension have thus been cited as factors
with the potential to affect rate (and extent) of API absorption
[9].
Drug release from PLG microsphere suspensions is pri-
marily governed by hydrolytic degradation of the micro-
spheres [9]. Hence, in addition to understanding geometry
of vehicle deposition, the spatial distribution of microspheres
relative to suspending vehicle could be of direct relevance to
microsphere in vivo performance. Additionally, study of the
temporal fate of injected microspheres may shed light on the
nature of particle deposition (single versus agglomerated
mass) at the injection site, and anatomical localisation rela-
tive to the suspending vehicle (co-localisation versus sieving
by the extracellular matrix), all of which contribute to mech-
anistic understanding of the impact of formulation, injection
or physiological parameters on the rate of API absorption. A
direct link between depot geometry of microsphere suspen-
sions and pharmacokinetic outcomes, however, is yet to be
established, attributable in part to the paucity of information
on the former.
Label-free imaging techniques are generally preferred to
circumvent inadvertent perturbation of formulation physico-
chemical properties. However, label-free techniques generally
suffer from disadvantages such as the requirement for tissue
excision and cryo-microtomy (e.g. mass spectrometry imag-
ing), insufficient focal depth for s.c. injection sites (e.g. high
frequency ultrasound, optical coherence tomography (OCT)
[10, 11]), or lack of resolution for the identification of weakly
attenuating small objects (such as PLG microspheres) (mag-
netic resonance imaging, MRI [12, 13], ultrasound) [14].
Herein, we describe a novel approach for simultaneously
visualising the post-injection deposition of PLG microspheres
and suspending vehicle in subcutaneous tissue using synchro-
tron X-ray micro-computed tomography (μCT). Data was
collected both in the presence and absence of X-ray contrast
agents. Ex vivo porcine abdominal tissue (≤12 h post mortem)
was used, given its anatomical similarity to human subcutane-
ous tissue, and since tissue viability was less important for
demonstration of technique feasibility. Data obtained from
synchrotron μCT measurements are compared to a modified
macrotomy technique adapted from Jockel et al. [15], and the
relative merits of the two approaches discussed. Potential ap-
plications of this technique in the mechanistic understanding
of API absorption from s.c. suspension formulations are
presented.
MATERIALS AND METHODS
Materials
Porcine abdominal tissue was obtained (≤12 h post mortem)
from a local abattoir from adult pigs that were not specifically
slaughtered for this study.
PLG microspheres were prepared in-house using a coacer-
vation method. Two suspending vehicles were selected with
differing physicochemical attributes; a low viscosity (25 mPa.s
at 20°C) non-aqueous vehicle, medium chain triglycerides
(MCT), and a more viscous (122 mPa.s at 20°C) aqueous
solution comprising 3% w/v carboxymethylcellulose sodium
(CMC-Na) in phosphate-buffered saline containing 0.1% w/v
polysorbate 20. MCTwas obtained fromCroda International
(Goole, UK). CMC-Na, and colorimetric dyes (Patent Blue V
and Solvent Green 3) were obtained from Sigma Aldrich
(Gillingham, UK).
Methods
Formulation preparation
For the μCT experiments, injections were performed in the
presence and absence of X-ray contrast agent. Where indicat-
ed, a 10% v/v concentration of appropriate iodine-based con-
trast agent (Lugol’s solution for the aqueous vehicle and
Lipiodol for the non-aqueous vehicle) was spiked into each
formulation vehicle. Formulations for macrotomy and optical
microscopy were spiked with 10% v/v (desired final volume) of
colorimetric dye (Patent Blue V and Solvent Green 3 for the
aqueous and nonaqueous vehicles, respectively).
Dyes and contrast agents were selected based on their sol-
ubility in the vehicle, hence the requirement for different
dyes/contrast agents for the aqueous and non-aqueous formu-
lations. A Mars Haake rheometer equipped with a C35/1°
CSL (222–1885) cone and plate was used to confirm no im-
pact of contrast agent on vehicle rheology at this
concentration.
Microsphere characterisation Scanning Electron Microscopy
(SEM)
The size and morphology of microspheres was assessed using
scanning electronmicroscopy (SEM) prior to suspension in the
formulation vehicle. The microspheres were sputter coated
with <5 nm of gold using a Quorum Q150R S (Quorum
Technologies UK Limited) and then SEM micrographs were
acquired using a Hitachi TM-1000 SEM microscope at an
accelerating voltage of 15 kV at magnifications of 500x and
5000x.
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Particle size characterisation (Laser diffraction)
The particle size distribution of the microspheres was deter-
mined by laser light scattering employing a Beckman-Coulter
LS 13320 Laser Diffraction Particle Size Analyzer consisting
of a wet dispersion module, a laser, a focusing lens, a photo-
sensitive detector, and a data processing unit.
Sample preparation
Abattoir-fresh porcine abdominal tissue was excised as either
small (3 × 3 cm) or large (10 × 10 cm) sections that were sub-
sequently injected with either contrast agent (Lugol’s solution
or Lipiodol) or colorimetric dye (Solvent Green 3 or Patent
Blue V) spiked formulation for μCT and macrotomy studies,
respectively. Porcine abdominal tissue is widely considered the
most relevant in terms of structure and composition to human
s.c. tissue [16] and was therefore considered appropriate for
use in the present study.
Injections were performed perpendicular to the tissue sec-
tion, and the device (23G, 6 mm hypodermic needle) main-
tained in situ for 8–10 s to reduce backflow.
Tissue samples for μCT were embedded at ambient tem-
perature in agarose gel (to minimise drying and associated
shrinkage effects during scans) and imaged immediately fol-
lowing agarose setting (i.e. 20 min).
For macrotomy, injected tissue sections were flash-frozen
and embedded in 2% w/v CMC paste to facilitate sectioning
(Fig. 1). This was followed by reference point was inserted in
each sample block to aid region of interest (ROI) alignment
during image analysis. Followingmounting in CMCpaste and
setting (i.e. 20–30min), samples were stored until further anal-
ysis in a− 80°C freezer.
Synchrotron x-ray micro-computed tomography (μCT) image
acquisition
X-ray synchrotron measurements were performed using
beamline I12 at Diamond Light Source (Oxfordshire, UK)
[17]. The beamline has built two detector systems with custom
designed optics coupled to the commercially available PCO
edge sCMOS camera. One detector system uses a single cam-
era and a choice of four magnification lens to image the opti-
cal light created by the scintillator. For this experiment the
largest field of view option was used (Module 1) and the mag-
nification has an effective pixel size of 18.5 μm and a field of
view (FOV) of 47 × 12 mm. The second detector (Large Field
of View detector) uses two PCO edge cameras mounted side
by side creating a single continuous field of view from two
images stitched together. This arrangement has an effective
pixel size of 21.5 μm and a field of view of 97 × 25 mm.
Further details of the two modules are provided in the supple-
mentary information section.
An incident X-ray beam energy of 70 keV was chosen to
maximise flux and minimise absorption. The sample-to-
detector distance was set to 1 m to generate propagation-
based phase contrast (otherwise known as ‘edge-enhance-
ment’) in the images [18]. For the collection of each tomo-
graphic dataset, 3600 projection images were acquired over
an angular range of 180°. Exposure times were 1.25 ms for
module 1 giving a scan time of 50 s and 40 ms for the LFV
detector giving a scan time of 150 s. Each tissue sample was
imaged 2–4 times in the vertical direction to create a stack of
tomograms covering its full height. A short scan time was used
to ensure minimal diffusion of vehicle during image
acquisition.
Image pre-processing and reconstruction
All tomographic pre-processing and reconstruction steps were
performed using in-house software and computing clusters at
Diamond Light Source. The python-based modular recon-
struction pipeline Savu [19] was used for the majority (a
process flow diagram outlines the steps in Fig. S1 of the
supplementary information section).
After the initial flat field correction, the LFV module pro-
jection images required stitching together, and the module 1
projection images were corrected for a slight lens distortion
effect [20].
Following stitching/distortion correction, a raven ring re-
moval filter was applied. GPU processed tomographic recon-
struction based on the filtered back projection algorithm was
then performed twice, separately for each data set: firstly,
applying standard attenuation-based reconstruction and then
as a second alternate phase-based reconstruction following an
additional filtering step. That step computes filtered projec-
tions using the single image phase retrieval approach devel-
oped by Paganin et al. [21] and yields additional area contrast
from the edge enhancement which is present in the unfiltered
data.
Finally, for both process branches, reconstructed sections
from the multiple scans corresponding to each sample were
combined and renumbered to produce a single set of consec-
utively numbered sections for each sample.
Microsphere detection
Software for the semi-automated detection of PLG micro-
spheres throughout the reconstructed tomographic section
stacks were custom-written for this application within IDL
9.4 (Harris Geospatial Solutions). Following the initial manual
inspection of the sections within each data set (using ImageJ)
for the presence of microspheres, a cursor-interactive code
was used to mark regions of interest (ROIs) within the stack
of sections. These ROIs were passed as coordinates into an
automated combined thresholding script which utilised both
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the standard and phase retrieved reconstructed data and ap-
plied a combination of intensity and texture thresholding (via
a high pass filter) to define a binary map marking the central
coordinates of each microsphere. Manual inspection was still
required to check for false positives and to determine the
thresholding values for each different sample. A schematic of
the workflow is given in the supplementary materials section
(Fig. S3).
Visualisation
Three-dimensional volume representations of the reconstruct-
ed data sets and marked microsphere distributions were gen-
erated within the three-dimensional visualisation and mea-
surement software package, Avizo 9.4 (Thermo Fisher
Scientific). Renderings of the contrast agent were generated
after segmentation via simple intensity thresholding of the
phase retrieved reconstructed data.
For the full manual segmentation of one representative
small tissue sample, the full phase retrieved reconstructed
dataset was used for the input, then downsized with 2 × 2 ×
2 binning. Inside the segmentation editor of Avizo each of the
main observed constituent materials (adipose and muscle
layers, contrast agent and air bubbles) were labelled with a
combination of thresholding and magic wand tools. Manual
tracing of the very low contrast fat-agarose interface was aided
with the use of a Wacom graphics tablet and then selection
interpolation. The corresponding unbinned binary map of the
sample microsphere distribution was added and convolved
with a gaussian shape function before separate volume ren-
dering. Movies were created through use of the Avizo anima-
tion editor.
Macrotomy
Macrotomy, digital photography and optical microscopy. In par-
allel to μCT measurements, a macrotomy method adapted
from Jockel et al [22] was used to characterise vehicle and
microsphere deposition for the same formulations. To aid
vehicle detection, the aqueous and non-aqueous vehicles were
spiked with Patent Blue V and Solvent Green 3, respectively.
Immediately post-injection, tissue samples were flash-
frozen and embedded in 2% w/v CMC paste. Cryo-
macrotomy was performed on the frozen tissue samples, and
excised tissue sections of 30 μm thickness were affixed to a
custom tape to aid visualisation with optical microscopy).
For macroscopic characterisation of vehicle depot, images
were captured using a Canon EOS digital camera fixed at
the same height relative to the tissue block. Microscopic as-
sessment of microsphere deposition in collected macrotomy
sections was also performed using a Zeiss scope A1 optical
microscope equipped with a 10x/0.25NA N-Achroplan ob-
jective lens. Multiple fields of view were acquired to assess the
localisation of microspheres within tissue cross sections.
Optical images of tissue sections from samples injected with
dyed formulation were processed in ImageJ (FIJI, v1.49p). All
images were imported into ImageJ as a virtual stack and
aligned relative to reference points. Subsequently, the image
stack was converted (pixel size 0.353 mm) to three-
dimensional stacks. Additionally, the voxel depth was calibrat-
ed as 180 μm to represent the frequency of sampling across
the sample depth during sectioning. Subsequently, all images
within the stack were thresholded manually to exclude the
contribution of undyed regions (background tissue contribu-
tion to signal) to the measured area. The thresholded image
stack was converted to a binary image to ease visualisation of
regions stained by the vehicle depot. To validate co-
localisation of the binary mask with dyed depot, image calcu-
lator was used. Subsequently, three-dimensional reconstruc-
tions of the binary stacks were rendered using an in-house
MatLab package. Further processing e.g. quantification of
% area stained by vehicle and volume of staining is possible
using Image J.
RESULTS
Microsphere characterisation
PLG microspheres manufactured using a double-emulsion
method were characterised by SEM and laser diffraction
Fig. 1 Porcine abdominal tissue
injected with microsphere
suspension and embedded in (A)
agarose and (B) injected frozen
tissue section undergoing
macrotomy.
   97 Page 4 of 11 Pharm Res           (2020) 37:97 
particle sizing (Fig. 2). Particle sizing by laser diffraction re-
vealed a particle size range of 20–100 μm diameter.
Assessment of dry microsphere morphology by SEM re-
vealed a raisin-like spherical morphology and evidence of lim-
ited surface porosity. Microsphere suspension in aqueous and
non-aqueous vehicles did not result in any apparent visual
changes in surface characteristics, particle porosity, and
morphology.
Visualisation of vehicle and microsphere distributions
by synchrotron x-ray micro computed tomography
Microspheres detected in the reconstructed μCT data were 3–
4 pixels in diameter as a function of their size and image
resolution, and exhibited varying visibility depending on the
acquisition noise levels. Those microspheres deposited in a
vehicle spiked with contrast agent were found to have brighter
pixel values corresponding to higher attenuation levels, pre-
sumably as a consequence of contrast agent surface-
adsorption (Fig. 3). Samples injected with aqueous vehicle in
combination with the contrast agent gave amuchmore diffuse
contrast than the nonaqueous vehicle meaning that tissue re-
gions with low vehicle concentration were less visible.
In the absence of contrast agent, microspheres were detect-
ed albeit with reduced sensitivity.
Weakly X-ray absorbing and at a length scale marginally
greater than the resolution of the system, the microspheres
presented some challenges in automating image analysis.
Material segmentation was not possible with intensity
thresholding alone. However, it was possible to exploit the
additional higher spatial frequencies within the unfiltered im-
ages due to the component of edge enhancement present, and
consistent particle morphology, with a texture based custom
thresholding method. When combined with intensity
thresholding it was possible to significantly both increase the
true positives and reduce the false positives of detected micro-
spheres in the subcutis. Embedding the tissue samples in aga-
rose made automatic segmentation challenging due to lack of
density difference between the agarose and porcine tissue.
Follow-up experiments, where samples were not embedded
in agarose, significantly improved this process with no detri-
mental impact on data quality.
Visual assessment of microsphere deposition within various
tissue samples revealed diffuse distribution of microspheres
throughout tissue sections, with regions of concentrated mi-
crosphere depots observed near the needle track (i.e. the in-
jection site).
During optimisation of tomographic image acquisition, the
utility of Module 1 and the LFV module for the in-situ imaging
of microspheres and vehicle was explored. The application of
LFV module was considered since larger tissue sections can be
imaged with the caveat of a lower resolution image being obtain-
ed. Overall, images generated from Module 1 were found to
offer superior contrast and resolution with the capability to probe
microsphere localisation when compared to the LFV setup.
Three-dimensional reconstruction of tomographic
images
Representative three-dimensional tomographic reconstructions,
including volume renderings of microsphere and vehicle depot
within porcine abdominal tissue are presented in Figs. 4 and 5.
Data presented above demonstrate the relative localisation
of injected microsphere suspensions within excised porcine
abdominal tissue. Microspheres and vehicle co-localised in
some regions of the depot, and the presence of microspheres
along the needle track close to the centre of injection was
evident for both formulations. However, some degree of sep-
aration in tissue distribution was observed between the
contrast-labelled vehicle and microspheres. The vehicle in
both cases migrated to site distal to the centre of the injection,
whereas, the microspheres were predominantly localized in
proximity to the centre of the injection.
A three-dimensional volume segmentation and rendering was
also created for one representative sample, which is utilised in the
graphical abstract and accompanying movie file. In Fig. 6, some
stills are included which show the important features of the mi-
crosphere distribution within the porcine tissue.
Following image segmentation and removal of tissue and
vehicle contribution (Fig. 6C-D), reconstructed microsphere
Fig. 2 Representative SEM
micrographs of dry PLG
microsphere morphology. (A) 500x
magnification (B) 2000x
magnification.
Pharm Res           (2020) 37:97 Page 5 of 11    97 
depots show evidence of microsphere deposition along the
needle tracks, with the bulk of microspheres located close to
the centre of injection in a few clusters (depots). Some individ-
ual microspheres were located at distal sites within the excised
tissue, consistent with the spread of injected (Fig. 6A-B).
Volume representations of aqueous and non-aqueous ve-
hicle depositions demonstrate microsphere identification (in
yellow) in the absence of contrast agent (Fig. 7A and B).
These were two of the larger porcine tissue samples imaged
with the LFV cameramodule. Therefore, this technique could
be applied in the absence of contrast agent, in scenarios where
the density difference between microspheres and vehicle was
sufficient, circumventing any associated pitfalls, for example,
the impact of labelling on formulation rheology.
Volume renderings of PLG microspheres in the absence
of contrast agent (Fig. 7) were created to evaluate the
feasibility for microsphere depot detection in ex vivo por-
cine tissue. The benefit of this representation is to examine
the relative anatomical localization of drug-loaded micro-
spheres within tissue through simultaneous visualization of
tissue layers and deposited microspheres without the need
for a contrast agent.
Fig. 4 Three-dimensional
visualisation of microsphere and
non-aqueous vehicle deposition
within porcine abdominal tissue
acquired using the module 1 setup.
Volume renderings of the
microspheres (yellow) and contrast
agent (blue) are overlaid onto
orthogonal reconstructions of
injected tissue samples. In (A) the
perspective camera view is shown,
and in each of (B), (C) and (D) the
top, longitudinal and transverse
views are presented
orthographically. The vertical height
shown is 18 mm, and the cross-
sectional diameter 42 mm.
Fig. 3 Reconstructed μCT data:
representative cross-sectional slice
from a standard reconstructed 3D
dataset of microspheres and non-
aqueous vehicle acquired using the
module 1 setup.
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Visualisation of vehicle and microspheres
by macrotomy and optical microscopy
Macroscopic assessment (i.e. photographic) of vehicle depot
geometry was assessed in tissue sections injected with micro-
sphere suspensions spiked with colorimetric dye (Patent Blue
V and Solvent Green 3 for the aqueous and non-aqueous
vehicles, respectively). To further visualise the three-
dimensional spread of the vehicle within the subcutis, tissue
background was removed, and depot reconstruction per-
formed. Accurate two- and three-dimensional visualisation
and quantification of vehicle spread for both vehicle types
was achieved using this method.
Microspheres were not detectable in the macroscopic
(photographic) images acquired during macrotomy section-
ing. Instead, every sixth tissue section was removed using ad-
hesive tape and microspheres were visualised using optical
microscopy. Microscopic assessment of PLG microsphere de-
position revealed that microspheres were localised in pockets
within tissue sections, and in close proximity to each other as
evidenced in the presented micrographs Fig. 8E-F.
Microsphere deposition was found to not always be co-
localized with the vehicle depot in some cases. There was
some evidence of tissue bursting around micrograph images,
consistent with the presence of particles within the
formulation.
DISCUSSION AND CONCLUSIONS
Controlled release microsphere suspension formulations are
an attractive treatment paradigm in the routine management
of a range of chronic conditions and offer the scope for im-
proved patient adherence [23].
Probing formulation fate following s.c. injection offers
the potential to understand the interplay between patient
inter-individual variability in physiology, and formula-
tion physicochemical attributes that can drive the design
and development of novel formulations and devices lead-
ing to consistent successful therapeutic outcomes [24,
25].
Recent advances in high resolution imaging and tools for the
characterisation of formulation material attributes have expand-
ed the toolbox available to study formulation-related parameters
and aid evaluation of their impact on biodistribution in the s.c.
tissue.
The scope of the present study was to demonstrate the
concept of synchrotron X-ray microcomputed tomography
(μCT) in simultaneous two- and three-dimensional visualisa-
tion of suspension formulation component distribution in
ex vivo porcine subcutis (s.c.). The formulations studied com-
prised PLGmicrospheres (20–100 μm diameter) suspended in
an aqueous or a non-aqueous vehicle, in the presence and
absence of a contrast agent.
Fig. 5 Three-dimensional visualisation of microsphere and aqueous vehicle deposition within porcine abdominal tissue acquired using the module 1 setup.
Volume renderings of microspheres (yellow) and contrast agent (blue) are overlaid onto orthogonal reconstructions of injected tissue samples. In (A) the
perspective camera view is shown, and in each of (B), (C) and (D) the top, longitudinal and transverse views are presented orthographically. The vertical height
is 18 mm, and the cross-sectional diameter 42 mm.
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We report the evaluation of PLG microsphere suspension
depot fate post-injection using previously reported
cryomacrotomy and synchrotron μCT. Macrotomy has pre-
viously been utilized to study insulin depot formation in sub-
cutaneous tissue, demonstrating mostly non-spherical depot
geometry. Injected insulin moves parallel to the skin surface
across a path of least resistance in between adipose cells with
depot geometry being dependent on tissue structure. At larger
injection volumes (exceeding 0.1 mL), perpendicular move-
ment relative to the skin surface occurs [15].
Macrotomy was implemented in this work to enable visu-
alization of PLGmicrosphere and vehicle fate following injec-
tion (Fig. 8). However, the low resolution of dyed vehicle
images posed a barrier to capturing the PLG microsphere
depot using the same setup. Instead, sections collected during
macrotomy were subjected to optical microscopy to evaluate
relative microsphere and vehicle localization on a microscopic
level. Findings from microscopic visualization and reconstruc-
tion of dyed vehicle depot, revealed similar observations to
previous work in which both lateral movement of the vehicle
across the tissue section was noted, with some evidence of
backflow against the needle track (injection site) [15, 26]. In
all samples there was evidence of significant microsphere re-
tention in proximity to the centre of the injection site, and
dyed vehicle migration in regions beyond microsphere locali-
zation. A key challenge with macrotomy was the labour-
Fig. 6 A three-dimensional snapshot of volume segmentation depicting aerial and transverse views respectively of the vehicle (A and B) and PLG microsphere
distribution (C and D), within a representative tissue section.
Fig. 7 Volume renderings of PLG microspheres in the absence of contrast agent (yellow) are overlaid onto orthogonal reconstructed CTsections of the tissue
sample, for (A) aqueous and (B) non-aqueous vehicles for images acquired using the LFV setup. The cross-sectional diameter represented here is 85 mm.
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intensive process for collection of tissue sections for microscop-
ic analysis of microsphere distribution. Subsequently, we per-
formed high-resolution synchrotron μCT to enable the simul-
taneous visualization of vehicle and microsphere depot.
Readout from synchrotron μCT indicate that this approach
can be used to visualize both microsphere and vehicle fate within
ex vivo tissue sections in contrast to the macrotomy setup where
two separate imaging approaches were utilized (Figs. 4 and 5).
With the macrotomy approach we were unable to reconstruct
the microsphere depot, significantly limiting assessment of post-
injection formulation fate (Fig. 8). Another key limitation associ-
ated with this approach was potential freezing effects on tissue
structure potentially impacting microsphere and vehicle localiza-
tion, and sectioning or removal of microspheres during
macrotomy. Findings from reconstructed μCT images showed
co-localization of microsphere (yellow) and vehicle (blue) along
the needle track and in proximity to the centre of the injection
site where the bulk ofmicrospheres accumulated. Taken together
with observations from cryomacrotomy, these findings confirm
that tissue structure restricts microsphere movement by acting as
a sieve, such thatmost injectedmicrospheres are retained close to
the centre of the injection site (Fig. 6C-D), and the injected vehi-
cle flows along the path of least resistance (Figs. 4, 5, 6). These
observations are in close agreement with previous observations of
suspension formulation fate described by Rasmussen et al [27,
28]. The vehicle was observed to migrate to distal sites in the
ex vivo tissue section consistent with previous findings on suspen-
sion injection fate where only a small number of particles are
deposited at sites distal to the centre of injection (Fig. 6C-
D).Using μCT we also visualized the relative anatomical depo-
sition of microspheres and vehicle within excised tissue.
Lab-based CT has previously been utilised to visualise and
quantify spatial distribution of soluble insulin formulations
[26, 27]. We selected synchrotron μCT for these experiments
Fig. 8 Representative two-dimensional sections (A and C), and reconstructed three-dimensional projections (B and D) of aqueous (A and B) and non-aqueous
(C and D) vehicle depots. Typical brightfield micrographs of microsphere distribution within tissue sections for non-aqueous (E) and aqueous microsphere (F)
suspensions (scale bar: 25 μm).
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because with an effective voxel size of 50 μm and resolution of
120 μm, resolution of microspheres in the 20–100 μm size
range could not be achieved with conventional lab-based
CT. Furthermore, the image acquisition time for lab-based
CT is significantly longer for the tissue section sizes investigat-
ed in this study (45 min versus 50 or 150 s). The resolution of
the technique reported here enabled the detection of individ-
ual deposited PLG microspheres (20–100 μm diameter) with-
in ex vivo porcine tissue, and visualization of subcutaneously-
injected microsphere suspension fate.
A component of the PLG microsphere visibility may be
attributed to the additional phase contrast present (edge
enhancement- where each material interface is highlighted by
a local intensity minimum directly adjacent to the maximum).
This is one of the several advantages of using a synchrotron X-
Ray source for the CT (other advantages include improved
contrast from the smaller energy bandwidth, shorter acquisition
times possible due to higher photon flux, etc).
Acquisition of freshly euthanised/excised tissue would be rec-
ommended before drawing conclusions on the impact of formu-
lation variables (volume, injection force, vehicle viscosity, lipophi-
licity etc.) on suspension formulation depot geometry, since
changes in mechanical properties of the tissue as a result of tem-
perature, hydration status and exposure to air likely reduce its
in vivo relevance. All ex vivo tissues sourced for these experiments
were acquired from an abattoir within hours of euthanasia.
As with the tomography approach used by Thomsen et al.,
the flexibility to segment various components enabled study of
elements of interest (e.g. vehicle, microspheres, and tissue
layers) [26].
In contrast to benchtop CT, the CTmethod and image anal-
ysis approach described here requires optional addition of con-
trast agent to the vehicle, without the need for resource intensive
remanufacture of polymeric microspheres incorporating contrast
agent or label, which can often be prohibitive in such imaging
studies. The uniform shape of the microspheres, in combination
with the high resolution of synchrotron μCT, enabled visualiza-
tion of individual microsphere particles within the ex vivo tissue
section in the presence and absence of contrast agent,
circumventing any caveats associated with contrast agent effects
on vehicle rheology and properties. The three-dimensional mi-
crosphere depot was reconstructed in the presence or absence of
background tissue elements (see supplementary video) to enable
assessment of relative anatomical localisation of formulation
components.
The true power of synchrotron μCT in combination with
the image analysis approach developed here is visualisation of
the in situ microsphere depot through edge enhancement,
without the need for contrast agent. This is one of the several
advantages associated with using a synchrotron X-Ray source
for the CT. Other advantages of this approach included rapid
image acquisition times due to higher photon flux, and im-
proved contrast from the smaller energy bandwidth.
Since tissue excision is currently a pre-requisite for high reso-
lution μCT imaging of formulation deposition, the technique is
limited to ex vivo tissue samples. A detailed account of depot
geometry impact on in vivo modelling of drug absorption is not
within the scope of this manuscript. While findings from the
present manuscript cannot be directly linked to the PK behav-
iour of injected PLGmicrospheres, the additional insights gained
into injection site depot geometry could feasibly contribute to
development of predictive in vitro or mechanistic in silico models
of subcutaneously- injected formulations in combination with
dissolution data. Findings from this work could also contribute
to a more thorough understanding of the role of depot geometry
on interspecies and interindividual differences in the rate and
extent of absorption, and impact of formulation variants or var-
iability in pharmacokinetics. To our knowledge there are no
reports of PLGmicrosphere suspension formulation in situ depot
geometry using synchrotron CT in the published literature.
Based on the successful outcome of this proof of concept study,
in vivo studies performed with PK sampling followed by eutha-
nasia and excision of the injection site in an appropriately-
designed timepoint preclinical study may be used to link depot
geometry findings directly to in vivo PK. Coupled with appro-
priate pharmacokinetic analyses of plasma concentrations, and
histological evaluation of immune cell infiltration, this approach
could foreseeably be employed to mechanistically investigate
the link between depot geometry and the rate/extent of absorp-
tion during formulation and device development.
This technique may also be applied to other routes of ad-
ministration including intramuscular injection, and alterna-
tive formulation types (in situ forming depots or crystalline/
amorphous microsuspensions).
With future work, and optimisation of experimental parame-
ters and image processing, microsphere detection could be im-
proved to enable greater automation and accuracy. Machine
learning tools for segmentation could also potentially be applied
to aid this process. Once accurate segmentation and labelling is
complete, tomographic analysis allows for almost unlimited sta-
tistical measurement of volume-based distributions.
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